Somatostatin Receptor PET/MR Imaging of Inflammation in Patients With Large Vessel Vasculitis and Atherosclerosis

Ćorović, Andrej; Wall, Conrad; Nus, Meritxell; Gopalan, Deepa; Huang, Yuan; Imaz, Maria; Zulcinski, Michal; Peverelli, Marta; Uryga, Anna; Lambert, Jordi; Bressan, Dario; Maughan, Robert; Pericleous, Charis; Dubash, Suraiya; Jordan, Natasha; Jayne, David; Hoole, Stephen P.; Calvert, Patrick A.; Dean, Andrew; Rassl, Doris M.; Barwick, Tara; Iles, Mark M.; Frontini, Mattia; Hannon, Greg; Manavaki, Roido; Fryer, Tim D.; Aloj, Luigi; Graves, Martin J.; Gilbert, Fiona J; Dweck, Marc R; Newby, David E.; Fayad, Zahi A.; Reynolds, Gary; Morgan, Ann W.; Aboagye, Eric O.; Davenport, Anthony P.; Jørgensen, Helle F.; Mallat, Ziad; Bennett, Martin R.; Peters, James E.; Rudd, James H.F.; Mason, Justin C.; Tarkin, Jason M.

doi:10.1016/j.jacc.2022.10.034

Cited by 34 publications

(11 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent data suggests the use of PET/MRI to better describe vessel wall inflammation and disease remission, progression, relapses in a non-irradiating way [ 34 ]. Moreover, it appears that future somatostatin receptor (SST2) PET/MRI will offer more accurate details on arterial inflammation and atherosclerotic lesions, since it can detect macrophages, pericytes, and adipocytes involved in the inflammation [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Refractory Takayasu’s Arteritis with Severe Coronary Involvement—Case Report and Literature Review

Cobilinschi

Grădinaru

Saulescu

et al. 2023

JCM

View full text Add to dashboard Cite

This report presents the case of a female patient diagnosed with Takayasu arteritis from childhood, with severe, refractory coronary involvement, leading to two acute coronary syndromes and multiple anginous episodes. Consequently, the patient suffered aorto-bicarotid bypass two times, multiple interventional procedures with stent implantation, balloon angioplasty, and up to ten repeated in-stent restenosis that required reinterventions, despite being on maximal immunosuppressive treatment. In recent years, various studies have been reported that aim to best characterize this particular type of vascular damage and to indicate optimal therapeutic options for treatment. The latter should be based on the activity of the underlying disease; however, no reliable markers are available in TA. The management of TA patients with coronary involvement continues to be a challenge and requires both drug and interventional techniques to avoid life-threatening events.

show abstract

Section: Discussionmentioning

confidence: 99%

Refractory Takayasu’s Arteritis with Severe Coronary Involvement—Case Report and Literature Review

Cobilinschi

Grădinaru

Saulescu

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…In both studies, visual delineation of the infarct territory was poor, reflecting rapid clearance of the tracer from the bloodstream. By contrast, patients with large-vessel vasculitis exhibit robust uptake of somatostatin receptor ligands in the vessel wall as measured by SUV mean and target-to-background ratios (48). Effective treatment with methotrexate resulted in marked reduction in the somatostatin receptor PET signal after a median of 9 mo (Fig.…”

Section: Smentioning

confidence: 99%

“…Effective treatment with methotrexate resulted in marked reduction in the somatostatin receptor PET signal after a median of 9 mo (Fig. 5) (48). Patients with acute myocardial infarction display localized uptake of 68 Ga-DOTATOC in segments corresponding to T2-weighted MRI edema and mild uptake in regions with a late gadolinium enhancement scar (49).…”

Section: Smentioning

confidence: 99%

“…Although complete clinical studies are lacking, the platform for imaging-based therapeutic guidance has been established in preclinical studies evaluating the prognostic value of inflammation imaging. Proinflammatory leukocyte markers, including glucose metabolism, CXCR4, CCR2, somatostatin receptor, and TSPO, have all demonstrated the predictive value of the early imaging signal for subsequent functional outcome (23,34,37,41,48). Taking this concept forward, the imaging time course can identify the optimal timing of therapy to support endogenous inflammatory resolution and repair.…”

Section: Imaging-guided Therapymentioning

confidence: 99%

See 1 more Smart Citation

Imaging Inflammation Past, Present, and Future: Focus on Cardioimmunology

Thackeray,

Lavine,

Liu

2023

J Nucl Med

View full text Add to dashboard Cite

Growing evidence implicates the immune system as a critical mediator of cardiovascular disease progression and a viable therapeutic target. Increased inflammatory cell activity is seen in the full spectrum of disorders from early-stage atherosclerosis through myocardial infarction, cardiomyopathy, and chronic heart failure. Although therapeutic strategies to modulate inflammation have shown promise in preclinical animal models, efficacy in patients has been modest owing in part to the variable severity of inflammation across individuals. The diverse leukocyte subpopulations involved in different aspects of heart disease pose a challenge to effective therapy, wherein adverse and beneficial aspects of inflammation require appropriate balance. Noninvasive molecular imaging enables tissue-level interrogation of inflammatory cells in the heart and vasculature to provide mechanistic and temporal insights into disease progression. Although clinical imaging has relied on 18 F-FDG as a nonselective and crude marker of inflammatory cell activity, new imaging probes targeting cell surface markers of different leukocyte subpopulations present the opportunity to visualize and quantify distinct phases of cardiac and vessel wall inflammation. Similarly, therapies are evolving to more effectively isolate adverse from beneficial cell populations. This parallel development of immunocardiology and molecular imaging provides the opportunity to refine treatments using imaging guidance, building toward mechanism-based precision medicine. Here, we discuss progress in molecular imaging of immune cells in cardiology from use of 18 F-FDG in the past to the present expansion of the radiotracer arsenal and then to a future theranostic paradigm of tracer-therapy compound pairs with shared targets. We then highlight the critical experiments required to advance the field from preclinical concept to clinical reality.

show abstract

“…SSTR2 PET/MRI showed major promise for diagnosis and therapeutic monitoring and was generally comparable to [ 18 F]FDG PET/CT, but with a very low background signal in the brain and heart. This allows for better assessment of nearby vascular involvement (23).…”

mentioning

confidence: 99%

¹⁸F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use

Leupe,

Ahenkorah,

Dekervel

et al. 2023

J Nucl Med

View full text Add to dashboard Cite

Somatostatin Receptor PET/MR Imaging of Inflammation in Patients With Large Vessel Vasculitis and Atherosclerosis

Cited by 34 publications

References 20 publications

Refractory Takayasu’s Arteritis with Severe Coronary Involvement—Case Report and Literature Review

Refractory Takayasu’s Arteritis with Severe Coronary Involvement—Case Report and Literature Review

Imaging Inflammation Past, Present, and Future: Focus on Cardioimmunology

¹⁸F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use

Contact Info

Product

Resources

About

Somatostatin Receptor PET/MR Imaging of Inflammation in Patients With Large Vessel Vasculitis and Atherosclerosis

Cited by 34 publications

References 20 publications

Refractory Takayasu’s Arteritis with Severe Coronary Involvement—Case Report and Literature Review

Refractory Takayasu’s Arteritis with Severe Coronary Involvement—Case Report and Literature Review

Imaging Inflammation Past, Present, and Future: Focus on Cardioimmunology

18F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use

Contact Info

Product

Resources

About

¹⁸F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use